Voyager Therapeutics, Inc.
VYGR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | -0.01 | 0.16 | 0.01 |
| FCF Yield | -5.76% | 20.56% | -6.41% | -54.01% |
| EV / EBITDA | -3.81 | 2.49 | -3.54 | -0.42 |
| Quality | ||||
| ROIC | -24.01% | 41.63% | -56.76% | -49.59% |
| Gross Margin | 100.00% | 98.22% | 84.87% | -97.21% |
| Cash Conversion Ratio | 0.24 | 0.59 | 0.27 | 0.75 |
| Growth | ||||
| Revenue 3-Year CAGR | 25.05% | 88.35% | -37.94% | -28.97% |
| Free Cash Flow Growth | -125.22% | 597.75% | 72.79% | 49.33% |
| Safety | ||||
| Net Debt / EBITDA | 0.35 | -0.38 | 1.70 | 1.07 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 7.95 | 43.15 |
| Cash Conversion Cycle | 20.49 | -8.53 | -99.65 | 12.92 |